CSBio CSBio

X
[{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","amount":"$67.5 million","upfrontCash":"$52.5 million","newsHeadline":"AZ licences Movantik rights to RedHill","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AstraZeneca"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BARHEMSYS\u00ae (amisulpride injection) Launched and Commercially Available in the US for the Treatment and Prevention of PONV","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Acacia Pharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Adds Israel Rights to Movantik\u00ae From AstraZeneca","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AstraZeneca"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acacia Pharma Completes Drawdown from \u20ac25 million Loan Facility from Cosmo Pharmaceuticals to Support US Launches of BARHEMSYS\u00ae and BYFAVO\u2122","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Acacia Pharma"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$23.5 million","upfrontCash":"Undisclosed","newsHeadline":"Acacia Pharma Proposed Capital Raising by Way of a Placing of New Ordinary Shares and Provides Update on Early Launch of BARHEMSYS\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Acacia Pharma"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Results for the Six Months ended 30 June 2021 - Barhemsys\u00ae and Byfavo\u00ae Launches Continue to Achieve Strong Hospital Formulary Adoption","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Acacia Pharma"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"$182.4 million","upfrontCash":"$78.5 million","newsHeadline":"Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Acacia Pharma"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"$182.4 million","upfrontCash":"$78.5 million","newsHeadline":"Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Acacia Pharma"},{"orgOrder":0,"company":"Ateria Health","sponsor":"Immuron","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immuron Strategic Investment in Leading Gut Health Biotech Ateria Health","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Ateria Health"},{"orgOrder":0,"company":"Ateria Health","sponsor":"Immuron","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$1.8 million","newsHeadline":"Immuron Completes Strategic Investment in Leading Gut Health Biotech Ateria Health","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Ateria Health"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The strategic investment advances Immuron’s objective to enter the broader IBS market with leading products and strengthen the distribution of Immuron’s Travelan® products through B2C online platforms and pharmacy and retail channels in target markets.

            Lead Product(s): Bovine Colostrum

            Therapeutic Area: Gastroenterology Product Name: Travelan

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Immuron

            Deal Size: Undisclosed Upfront Cash: $1.8 million

            Deal Type: Financing November 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The investment is made with the intention to enter into reciprocal distribution agreement for Travelan® (bovine colostrum) in the U.K. market and JUVIA™ in Australian and North American markets.

            Lead Product(s): Bovine Colostrum

            Therapeutic Area: Gastroenterology Product Name: Travelan

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Immuron

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing October 13, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            With the acquisition, addition of the two products expands the presence in acute care space, BARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection) join Eagle portfolio.

            Lead Product(s): Amisulpride

            Therapeutic Area: Gastroenterology Product Name: Barhemsys

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eagle Pharmaceuticals

            Deal Size: $182.4 million Upfront Cash: $78.5 million

            Deal Type: Acquisition June 09, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Opportunity for Eagle’s highly skilled hospital-based salesforce to integrate and promote BYFAVO and BARHEMSYS and to leverage longstanding relationships to realize the full potential of these assets.

            Lead Product(s): Amisulpride

            Therapeutic Area: Gastroenterology Product Name: Barhemsys

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eagle Pharmaceuticals

            Deal Size: $182.4 million Upfront Cash: $78.5 million

            Deal Type: Acquisition March 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Barhemsys® is an intravenous formulation of amisulpride, a selective dopamine antagonist. It is approved in the US for treatment and prophylaxis of PONV, alone and in combination with other antiemetics.

            Lead Product(s): Amisulpride

            Therapeutic Area: Gastroenterology Product Name: Barhemsys

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The net proceeds of the Placing are intended to be used To meet its sales force and marketing costs relating to BARHEMSYS® and BYFAVO™ including brand development and engagement with key opinion leaders, healthcare professionals and medical conference and speaker programs.

            Lead Product(s): Amisulpride

            Therapeutic Area: Gastroenterology Product Name: Barhemsys

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $23.5 million Upfront Cash: Undisclosed

            Deal Type: Financing February 18, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Company plans to deploy this capital to support its ongoing US launches of BARHEMSYS® (amisulpride injection) for postoperative nausea & vomiting and BYFAVO™ (remimazolam for injection) for procedural sedation.

            Lead Product(s): Amisulpride

            Therapeutic Area: Gastroenterology Product Name: Barhemsys

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cosmo Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing October 09, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            RedHill Biopharma has gained the rights to Movantik (naloxegol)1 in Israel from AstraZeneca. RedHill now holds the worldwide rights to Movantik, excluding Europe and Canada. RedHill to evaluate partnering opportunities for commercialization of Movantik in Israel.

            Lead Product(s): Naloxegol Oxalate

            Therapeutic Area: Gastroenterology Product Name: Moventig

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: RedHill Biopharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 08, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BARHEMSYS® (amisulpride injection) has been launched and is now commercially available in the US for order and delivery to customers through major wholesalers and specialty distributors.

            Lead Product(s): Amisulpride

            Therapeutic Area: Gastroenterology Product Name: Barhemsys

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 24, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik in the US, which has now been transferred to RedHill.

            Lead Product(s): Naloxegol Oxalate

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: RedHill Biopharma

            Deal Size: $67.5 million Upfront Cash: $52.5 million

            Deal Type: Divestment April 02, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY